300482 Stock Overview
An in vitro diagnostics company, engages in the research and development, production, and sale of point-of-care testing products, and rapid diagnosis and chronic disease management solutions in China.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Guangzhou Wondfo Biotech Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥27.89 |
| 52 Week High | CN¥32.64 |
| 52 Week Low | CN¥20.52 |
| Beta | 0.58 |
| 1 Month Change | 0.80% |
| 3 Month Change | 2.99% |
| 1 Year Change | -8.35% |
| 3 Year Change | -60.72% |
| 5 Year Change | 8.78% |
| Change since IPO | 466.52% |
Recent News & Updates
Guangzhou Wondfo BiotechLtd's (SZSE:300482) Solid Earnings May Rest On Weak Foundations
Apr 29
A Piece Of The Puzzle Missing From Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Share Price
Mar 27Recent updates
Guangzhou Wondfo BiotechLtd's (SZSE:300482) Solid Earnings May Rest On Weak Foundations
Apr 29A Piece Of The Puzzle Missing From Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Share Price
Mar 27There Are Reasons To Feel Uneasy About Guangzhou Wondfo BiotechLtd's (SZSE:300482) Returns On Capital
Feb 29Shareholder Returns
| 300482 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | -0.07% | -1.0% | -0.4% |
| 1Y | -8.3% | -14.6% | -12.6% |
Return vs Industry: 300482 exceeded the CN Medical Equipment industry which returned -14.4% over the past year.
Return vs Market: 300482 exceeded the CN Market which returned -11.8% over the past year.
Price Volatility
| 300482 volatility | |
|---|---|
| 300482 Average Weekly Movement | 6.4% |
| Medical Equipment Industry Average Movement | 6.0% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 9.9% |
| 10% least volatile stocks in CN Market | 4.0% |
Stable Share Price: 300482 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300482's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 3,404 | Zhongxiong Peng | www.wondfo.com.cn |
Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, and sale of point-of-care testing products, and rapid diagnosis and chronic disease management solutions in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious, fertility, and sexually transmitted diseases, as well as immunofluorescence devices to detect cardiovascular diseases, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor, and other diseases. It also provides blood coagulation, optical coagulation, and dry chemistry analyzers, as well as automatic chemiluminescence immunoassay and molecular diagnostic analyzers.
Guangzhou Wondfo Biotech Co.,Ltd Fundamentals Summary
| 300482 fundamental statistics | |
|---|---|
| Market cap | CN¥13.06b |
| Earnings (TTM) | CN¥502.28m |
| Revenue (TTM) | CN¥2.79b |
26.0x
P/E Ratio4.7x
P/S RatioIs 300482 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300482 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.79b |
| Cost of Revenue | CN¥1.04b |
| Gross Profit | CN¥1.75b |
| Other Expenses | CN¥1.25b |
| Earnings | CN¥502.28m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.07 |
| Gross Margin | 62.71% |
| Net Profit Margin | 17.97% |
| Debt/Equity Ratio | 10.1% |
How did 300482 perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield35%
Payout RatioDoes 300482 pay a reliable dividends?
See 300482 dividend history and benchmarks| Guangzhou Wondfo BiotechLtd dividend dates | |
|---|---|
| Ex Dividend Date | Jun 05 2024 |
| Dividend Pay Date | Jun 05 2024 |
| Days until Ex dividend | 4 days |
| Days until Dividend pay date | 4 days |
Does 300482 pay a reliable dividends?
See 300482 dividend history and benchmarks